Liraglutide: The First Daily GLP-1
A 31-amino-acid GLP-1 analogue with a C16 fatty-acid tail. Approved as Victoza (T2D) and Saxenda (obesity) before semaglutide replaced it as first-line.
How It Works
Binds the GLP-1 receptor in pancreas, gut, and brain. Triggers glucose-dependent insulin secretion (low hypoglycemia risk) and suppresses glucagon.
Food stays in the stomach longer, increasing satiety and reducing post-meal glucose spikes. The mechanism behind most GI side effects.
Acts on hypothalamic GLP-1 receptors to reduce hunger and food reward. Patients report eating less without conscious effort.
C16 fatty-acid acylation extends half-life to ~13 hours via albumin binding. Requires daily subcutaneous injection — semaglutide's C18 diacid extends to ~7 days.
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- Mean 8.4 kg (≈8%) weight loss at 56 weeks at 3.0 mg/day in non-diabetics (SCALE Obesity, NEJM 2015).
- Reduces HbA1c by ~1.0–1.5% in T2D at 1.2–1.8 mg/day (LEAD program).
- Approved for adolescents (12+) with obesity — broader pediatric data than semaglutide.
- Reduces apnea-hypopnea index by ~12 events/hour in obese OSA patients.
- Cardiovascular benefit shown in LEADER trial (13% MACE reduction in T2D + high CV risk).
- Same drug class as semaglutide, tirzepatide — same dose-titration logic for GI tolerability.
- Long-term (>5 yr) head-to-head vs semaglutide on weight maintenance.
- Whether daily vs weekly dosing changes adherence-adjusted real-world outcomes meaningfully.
- Optimal protocol for off-cycle weight maintenance after stopping.
- Long-term thyroid C-cell tumor risk in humans (boxed warning is rodent-data driven).
- Whether the daily-dosing requirement gives any clinical advantage over weekly semaglutide.
Frequently Asked Questions
What is liraglutide?
Liraglutide is a once-daily GLP-1 receptor agonist sold as Victoza (1.2–1.8 mg, type 2 diabetes) and Saxenda (3.0 mg, chronic weight management). It was the first long-acting GLP-1 analog approved for obesity in 2014 and produced ~8% mean weight loss over 56 weeks in the SCALE Obesity trial.
How does liraglutide compare to semaglutide?
Same drug class, same mechanism. Semaglutide has a longer half-life (once-weekly vs once-daily) and produces nearly twice the weight loss in head-to-head data (~15% vs ~8% over 1+ year). Liraglutide remains useful when daily dosing is preferred, in adolescents, or when semaglutide is unavailable.
Why is liraglutide injected daily when semaglutide is weekly?
Liraglutide uses a C16 monoacyl fatty-acid modification that extends its half-life to ~13 hours via albumin binding. Semaglutide uses a C18 fatty diacid linker that pushes the half-life to ~7 days, enabling weekly dosing. The structural change came directly from learning what worked with liraglutide.
What are the side effects of liraglutide?
Most common: nausea, vomiting, diarrhea, constipation, and injection-site reactions — mostly mild-to-moderate and usually subside after dose escalation. Boxed warning for thyroid C-cell tumors based on rodent data; contraindicated with personal/family history of medullary thyroid carcinoma or MEN-2.
Is liraglutide still used in 2026?
Yes, but mostly as second-line. Most new GLP-1 prescriptions now go to semaglutide or tirzepatide for better efficacy and weekly dosing. Liraglutide retains use in pediatric obesity (12+), patients who prefer daily dosing, or where supply chain constraints favor older GLP-1s.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
Educational purposes only. Not medical advice.
Information on this page is for research and educational use only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any decision related to a peptide, drug, or supplement.
HighPeptides may earn an affiliate commission from qualifying purchases via Amazon and other partner links on this page, at no extra cost to you.